The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BIOVF | +12.88% | +79.32% | +12.39% | +236% |
| S&P | +18.37% | +110.18% | +16.02% | +309% |
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life-threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $817.03M | 23.5% |
| Gross Profit | -$132.81M | -129.3% |
| Gross Margin | -16.26% | -84.7% |
| Market Cap | $10.35B | -3.4% |
| Market Cap / Employee | $5.48M | -7.3% |
| Employees | 1.9K | 4.2% |
| Net Income | -$304.18M | -316.5% |
| EBITDA | $1.09B | 279.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $110.47M | 88.5% |
| Accounts Receivable | $613.39M | 33.0% |
| Inventory | 493 | 25.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $961.29M | -16.9% |
| Short Term Debt | $483.57M | -20.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -0.38% | -5.1% |
| Return On Invested Capital | 8.01% | -0.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $198.39M | 88.6% |
| Operating Free Cash Flow | $199.28M | 85.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 32.89 | 26.72 | 26.31 | 24.84 | -44.46% |
| Price to Book | 2.60 | 2.70 | 2.59 | 2.53 | -19.17% |
| Price to Sales | 4.05 | 4.03 | 4.04 | 3.82 | -17.60% |
| Price to Tangible Book Value | -4.63 | -5.83 | -6.18 | -6.84 | 43.87% |
| Price to Free Cash Flow TTM | 14.89 | 14.83 | 16.66 | 14.53 | -20.54% |
| Enterprise Value to EBITDA | 47.52 | 50.07 | 52.67 | 10.90 | -75.77% |
| Free Cash Flow Yield | 6.7% | 6.7% | 6.0% | 6.9% | 25.85% |
| Return on Equity | 10.5% | 10.3% | 11.1% | -0.7% | -107.30% |
| Total Debt | $1.51B | $1.40B | $1.34B | $1.44B | -18.03% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
